


Peptide Therapeutics Market to reach USD 83.80 Billion by 2035 at 6.7% CAGR

Peptide Therapeutics Market to Surge from USD 46.73 Billion in 2026 to USD 83.80 Billion by 2035—By GLP-1 Multi-Agonist Expansion, AI-Driven Discovery Platforms

NY, CA, UNITED STATES, August 17, 2026 /EINPresswire.com/ -- As per Market Research Future, the [global Peptide Therapeutics](#)

[Market size](#) is projected to reach USD 83.80 Billion by 2035 from USD 46.73 Billion in 2026, at a CAGR of 6.7% during the forecast period 2026–2035. The market base was estimated at USD 43.80 Billion in 2025.



The 6.7% CAGR—anchored by a structural shift in how metabolic and oncological diseases are treated—is propelled by three primary forces: the clinical and commercial success of incretin-class therapies, which have validated peptides as a dominant modality and driven multi-billion-dollar investment; AI-enabled peptide discovery platforms that are compressing lead-optimization cycles from months to weeks; and long-awaited breakthroughs in oral delivery that are dismantling the historical reliance on parenteral administration, widening the addressable patient population.

Global pharmaceutical companies and regulatory bodies are amplifying this momentum. Novo Nordisk committed over USD 6 Billion in manufacturing expansion between 2023 and 2025, while Roche and Novartis each closed billion-dollar licensing deals for next-generation multi-agonist candidates. The FDA granted 34 fast-track designations to peptide-based candidates in 2024 alone—nearly double the 2020 figure—and the EMA's orphan drug framework continues to compress development timelines for peptide therapies targeting rare diseases. Combined, these forces are creating the clinical infrastructure, manufacturing capacity, and regulatory tailwinds on which the Peptide Therapeutics Market depends.

Request A Free Sample:

Key Market Trends & Growth Drivers

GLP-1 and Multi-Agonist Clinical Expansion

The blockbuster commercial success of semaglutide and tirzepatide has redrawn pharma portfolio priorities. Combined global revenues for GLP-1 receptor agonists surpassed USD 50 Billion in 2024, validating peptides as a dominant modality in metabolic medicine. Novo Nordisk's CagriSema (amylin-GLP-1 dual agonist) and Eli Lilly's retatrutide (triple agonist) represent the next wave—with Phase III data showing weight-loss efficacy exceeding 20%, widening the addressable population well beyond Type 2 diabetes into obesity, NASH, and cardiovascular risk reduction. This clinical breadth makes the Peptide Therapeutics Market increasingly central to big-pharma growth strategies, with CMS spending on GLP-1 agonists exceeding USD 24 Billion in 2024 alone.

AI-Enabled Peptide Design Platforms

Machine-learning models trained on peptide–receptor binding datasets are compressing lead-identification from 18 months to under 8 weeks. Startups such as Absci, Evotec, and Peptilogics raised a combined USD 1.3 Billion between 2023 and 2025 to build generative-AI platforms that optimize peptide sequences for stability, selectivity, and oral bioavailability simultaneously. Large pharma houses including AstraZeneca and Sanofi have embedded these tools into their discovery workflows, signaling that computational design is no longer experimental but an operational standard reshaping the Peptide Therapeutics Market pipeline.

Oral Peptide Delivery Breakthroughs

Parenteral administration has historically limited peptide therapy adoption in primary-care settings. The FDA approval of oral semaglutide (Rybelsus) and the advancing pipeline of SNAC-based and permeation-enhancer-enabled oral formulations are dismantling that barrier. Novo Nordisk's Phase III oral amycretin data, reported in late 2024, demonstrated non-inferiority to injectable dosing in glycemic control, suggesting that oral peptides could capture 25–30% of new prescriptions in metabolic indications by 2030. This shift directly expands the addressable patient population of the Peptide Therapeutics Market and opens a primary-care channel for peptide prescribing.

Manufacturing Scale-Up and Continuous-Flow SPPS

Legacy batch-mode solid-phase synthesis is giving way to continuous-flow platforms and recombinant expression systems that cut cost-of-goods by 20–30% on longer sequences. Continuous-flow SPPS reduces solvent consumption by 40% and cycle times by 50% versus batch processing. Big-pharma investment underscores the conviction: Novo Nordisk announced a USD

4.1 Billion investment in a peptide API manufacturing facility in North Carolina in June 2024, the largest single-site peptide production expansion in U.S. history.

Ask for Customization:

https://www.marketresearchfuture.com/ask_for_customize/22758

Market Segment Insights

BY MARKETING TYPE

Branded Peptides: Dominant segment with ~66% revenue share in 2025, sustained by patent-protected incretin and oncology franchises. Incretin-class blockbusters—semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound)—enjoy robust patent protection through the late 2020s, supporting premium revenue shares through demonstrated cardiovascular and weight-loss outcomes.

Generic Peptides: Fastest-growing segment at 8.9% CAGR (2026–2035), driven by patent cliffs on first-generation GLP-1 receptor agonists. Biosimilar-style regulatory pathways in the EU and accelerated ANDA filings in the US are expected to bring competitively priced alternatives to market from 2028 onward.

BY APPLICATION

Oncology: Largest segment with 38.2% revenue share in 2025, reflecting the clinical maturation of somatostatin analogs (lanreotide, octreotide) and the rapid scaling of radioligand peptide therapies. With over 80 peptide–drug conjugate (PDC) candidates in clinical trials, oncology remains the single largest pipeline expansion vector in the market.

Gastrointestinal Disorders: Fastest-growing application at 12.7% CAGR (2026–2035), propelled by label expansions of GLP-1 agonists into NASH, gastroparesis, and inflammatory bowel conditions.

Metabolic Disorders: Represents approximately USD 12.85 Billion in 2025, driven by global obesity and diabetes prevalence.

BY ROUTE OF ADMINISTRATION

Parenteral (Subcutaneous, Intravenous): Dominant with roughly 75% of 2025 volumes, reinforcing the clinical preference for injectable delivery to achieve therapeutic bioavailability.

Oral: Fastest-growing segment at 13.8% CAGR (2026–2035), led by permeation-enhancer and enteric-coating technologies. Successful commercialization of advanced oral formulations would fundamentally alter prescribing patterns and add an estimated USD 8–12 Billion in incremental

revenue by 2032.

BY TECHNOLOGY

Solid-Phase Peptide Synthesis (SPPS): Largest segment with 48.3% share in 2025, remaining the workhorse platform for sequences under 50 residues. Its dominance is underpinned by deep clinical standardization and widespread availability of automated synthesizers.

Recombinant Expression: Fastest-growing technology at 14.7% CAGR (2026–2035), driven by the clinical shift toward longer, structurally complex peptide chains. Recombinant and hybrid expressions offer dramatic cost-of-goods reductions and superior fermentation scale compared to traditional multi-step chemical coupling.

BY END USER

Hospitals & Clinics: Largest end-user segment with 45.2% share in 2025, anchored by the need for parenteral administration, specialized cold-chain infrastructure, and professional monitoring that can only be delivered in clinical settings.

Pharmaceutical & Biotech Companies: Fastest-growing end-user at 13.5% CAGR (2026–2035), reflecting heavy corporate investments into novel peptide drug discovery platforms, expanding multi-agonist clinical pipelines, and the critical need to scale internal manufacturing.

Read Detailed Insights:

<https://www.marketresearchfuture.com/reports/peptide-therapeutics-market-22758>

Regional Outlook

North America — Dominant Market (~41% Share, 2025)

United States: Generates approximately 82.5% of North American revenue, driven by broad commercial and Medicare Part D coverage for semaglutide and tirzepatide. The country's dense clinical-trial ecosystem and FDA fast-track pipeline sustain premium pricing and innovation leadership.

Canada: Contributes through expanding CADTH reimbursement for peptide oncology drugs.

Mexico: Growing on insulin access programs and private-sector demand. The region's leadership rests on deep payer coverage and the structural shift toward multi-agonist therapies.

Europe — Second Largest (USD 11.83 Billion, 2025)

Germany: Leads the region, driven by a strong biotech corridor and early radioligand therapy

uptake, growing at a 6.1% CAGR.

United Kingdom: Contributes USD 2.28 Billion in 2025, with NHS long-term plans and NICE appraisals accelerating peptide access.

France: Accounts for 15.8% of regional share through centralized hospital purchasing for oncology peptides.

Italy: Holds 12.1% of regional share with a biosimilar-friendly regulatory stance.

Spain: Represents 9.4% of regional share on growing obesity treatment demand.

Nordic Countries: Contribute 7.3% of regional share through high per-capita healthcare spending.

Russia: Holds 4.5% of regional share through domestic production mandates.

Rest of Europe: The market is shaped by EMA's PRIME scheme accelerating peptide candidate reviews and EU-level horizon-scanning identifying multi-agonist peptides as a priority therapeutic class.

Asia-Pacific — Fastest-Growing Region (13.8% CAGR, 2026–2035)

China: Holds the largest regional share at 34.5%, fueled by domestic CDMO scale-up and NMPA accelerated approvals. The National Medical Products Administration granted over 20 peptide-related approvals between 2023 and 2025.

India: Fastest-growing major market at 14.2% CAGR, propelled by the PLI-driven API manufacturing and rising diabetes burden. Dedicated peptide manufacturing SEZs in Hyderabad and Ahmedabad are creating a globally competitive cost base.

Japan: Contributes USD 2.65 Billion in 2025 through its aging population and advanced oncology peptide adoption.

South Korea: Leverages biosimilar expertise extending into peptide generics, holding 8.7% of regional share.

ASEAN: Growing at a steady pace with expanding metabolic disease treatment access.

Rest of Asia-Pacific: Incremental clinical infrastructure investments supporting growth. The region's combined contribution anchors the global volume base for metabolic and oncology peptide demand.

South America — Growing Presence (USD 2.54 Billion, 2025)

Brazil: Anchors the region at 62% of revenue, with ANVISA regulatory alignment with ICH and SUS procurement expansion. The Unified Health System expanded peptide procurement in 2024 to include semaglutide for Type 2 diabetes, significantly widening the addressable patient pool.

Argentina: Grows on private-sector peptide demand, holding 19.5% of regional share.

Rest of South America: Early-stage market development through public-health insulin and peptide programs.

Middle East & Africa — Emerging Opportunity (4.2% Share, 2025)

Saudi Arabia: Leads the region with 31% of regional share, driven by Vision 2030 healthcare investment.

UAE: Positions itself as a medical tourism hub with advanced hospital infrastructure, holding 24.5% of regional share.

South Africa: Represents the largest pharmaceutical market in Sub-Saharan Africa, contributing 18% of regional share.

Egypt: Population-driven demand for metabolic therapies.

Rest of MEA: Gradual formulary expansion supported by government healthcare modernization. Saudi Arabia's Vision 2030 allocations and the UAE's pharma free zones are creating logistical gateways for the broader Peptide Therapeutics Market.

Competitive Landscape and Recent Developments

The Peptide Therapeutics Market is moderately concentrated, with the top five players capturing an estimated 45–55% of global revenue. Novo Nordisk and Eli Lilly together command disproportionate share through their incretin franchises, while a second tier of diversified pharma and specialty manufacturers compete across oncology, rare disease, and endocrine indications. The competitive dynamic balances blockbuster-driven concentration at the branded end with increasing fragmentation in the generic and CDMO segments.

KEY COMPANIES AND RECENT MILESTONES

Novo Nordisk (June 2024): Announced a USD 4.1 Billion investment in a peptide API manufacturing facility in North Carolina, the largest single-site peptide production expansion in U.S. history. Commanding an estimated ~18–22% of global revenue, the company maintains a dominant incretin franchise with semaglutide (Ozempic/Wegovy) and a promising CagriSema

pipeline.

Eli Lilly and Company (January 2025): Reported positive Phase III results for orforglipron, an oral non-peptide GLP-1 agonist, intensifying competitive pressure on injectable peptide franchises. With an estimated ~14–18% revenue share, the company leads the multi-agonist pipeline with tirzepatide (Mounjaro/Zepbound) and retatrutide.

Sanofi: Maintains a strong oncology peptide portfolio with lanreotide (Somatuline) and insulin glargine, holding an estimated ~5–8% revenue share with a robust biosimilar defense strategy.

AstraZeneca: Investing in peptide-based oncology candidates and computational peptide design integration, holding an estimated ~4–6% revenue share.

Takeda Pharmaceutical: Established oncology and GI peptide presence with leuprolide (Lupron) and a GI peptide pipeline, holding an estimated ~3–5% revenue share.

Bachem Holding: The leading independent peptide API manufacturer, holding an estimated ~2–4% revenue share as a critical CDMO supplier.

Ipsen: Specialty endocrinology and oncology focus with lanreotide and triptorelin, holding an estimated ~3–5% revenue share.

Teva Pharmaceutical: Building a cost-competitive generic peptide portfolio across mature markets, holding an estimated ~2–4% revenue share.

Future Outlook: 2026–2035

By 2030, an estimated 60% of peptide lead candidates will originate from AI-driven design platforms, according to biopharma digitization forecasts. Automated robotic synthesis and closed-loop AI-experiment cycles will compress discovery-to-IND timelines from five years to under three, reshaping the competitive tempo of the Peptide Therapeutics Market.

Oral peptide formulations will fundamentally alter prescribing patterns, with permeation-enhancer platforms and enteric-coating technologies progressing through Phase III trials. Successful commercialization would open a primary-care channel for peptide prescribing, moving it from endocrinologists to general practitioners and adding USD 8–12 Billion incremental revenue by 2032.

Platform economics and modular peptide manufacturing will shift the economics from capital-intensive mega-plants toward distributed, on-demand production. Continuous-flow SPPS and modular biomanufacturing pods could reduce peptide API costs by 35% in low- and middle-income countries by 2032, enabling broader access to the Peptide Therapeutics Market globally.

The convergence with radiopharmaceuticals and theranostics is creating a paradigm where diagnosis and treatment use the same molecular scaffold. Novartis's radioligand therapy franchise (Lutathera, Pluvicto) generated USD 2.5 Billion in 2024, and over 150 peptide-radiopharmaceutical conjugates are in clinical development, redefining oncology's share within the Peptide Therapeutics Market.

ESG and green chemistry will become competitive differentiators, with the ACS Green Chemistry Institute publishing guidelines in 2024 calling for a 50% reduction in DMF and NMP usage by 2030. Companies that adopt water-based coupling strategies and solvent-recovery systems will gain both regulatory goodwill and operational cost advantages.

Data-driven companion diagnostics and personalized dosing will improve response rates by 15–20%, reducing payer hesitancy around high-cost branded peptides. Companies that bundle diagnostic assays with peptide therapeutics create closed-loop ecosystems that strengthen reimbursement positioning and deepen market penetration.

The decade ahead will be defined by oral delivery breakthroughs, AI-driven candidate design, and manufacturing innovation reshaping the competitive landscape of the Peptide Therapeutics Market to its USD 83.80 Billion 2035 destination.

More Related Research Insights:

<https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531>

<https://www.marketresearchfuture.com/reports/medical-pendant-market-6681>

<https://www.marketresearchfuture.com/reports/medical-marijuana-market-6470>

<https://www.marketresearchfuture.com/reports/peripheral-artery-disease-market-1540>

<https://www.marketresearchfuture.com/reports/mouth-ulcer-treatment-market-6421>

<https://www.marketresearchfuture.com/reports/medical-footwear-market-43314>

<https://www.marketresearchfuture.com/reports/mesotherapy-market-11874>

<https://www.marketresearchfuture.com/reports/varicose-veins-treatment-market-6888>

<https://www.marketresearchfuture.com/reports/protein-stability-analysis-market-39528>

<https://www.marketresearchfuture.com/reports/sternal-closure-systems-market-6137>

Larry Wilson

WantStats Research And Media Pvt. Ltd.

+1 855-661-4441

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/934779823>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.